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Open access under the ElsThe pyrH-encoded uridine 50-monophosphate kinase (UMPK) is involved in both de novo and salvage syn-
thesis of DNA and RNA precursors. Here we describeMycobacterium tuberculosis UMPK (MtUMPK) cloning
and expression in Escherichia coli. N-terminal amino acid sequencing and electrospray ionization mass
spectrometry analyses conﬁrmed the identity of homogeneous MtUMPK. MtUMPK catalyzed the phos-
phorylation of UMP to UDP, using ATP–Mg2+ as phosphate donor. Size exclusion chromatography showed
that the protein is a homotetramer. Kinetic studies revealed that MtUMPK exhibits cooperative kinetics
towards ATP and undergoes allosteric regulation. GTP and UTP are, respectively, positive and negative
effectors, maintaining the balance of purine versus pyrimidine synthesis. Initial velocity studies and sub-
strate(s) binding measured by isothermal titration calorimetry suggested that catalysis proceeds by a
sequential ordered mechanism, in which ATP binds ﬁrst followed by UMP binding, and release of prod-
ucts is random. As MtUMPK does not resemble its eukaryotic counterparts, speciﬁc inhibitors could be
designed to be tested as antitubercular agents.
 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Human tuberculosis (TB),1 mainly caused by Mycobacterium
tuberculosis, is a major cause of illness and death worldwide.
M. tuberculosis is a remarkably successful pathogen that latently in-
fects one third of theworld population [1] and, despite the availabil-
ity of effective chemotherapy and moderately protective vaccine,of Science and Technology on
PES) and the Millennium Ini-
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evier OA license.the tubercle bacillus continues to claim more lives than any other
single infectious agent [2]. Increasing HIV–TB co-infections [2], the
emergence of multidrug-resistant (MDR), extensively drug-resistant
(XDR) [3], and, more recently, of totally drug-resistant strains (TDR)
[4] have highlighted the need for the development of new therapeutic
strategies to combat TB. Strategies based on the discovery of new tar-
gets for antimycobacterial agent development include elucidation of1 Abbreviations used: ADP, adenosine 50-diphosphate; ATP, adenosine 50-triphos-
phate; CMP, cytosine 50-monophosphate; CTP, cytosine 50-triphosphate; dCMP,
deoxycytosine 50-monophosphate; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic
acid; dTMP, deoxythymidine 50-monophosphate; ESI-MS, electrospray ionization
mass spectrometry; FDA, Food and Drug Administration; GTP, guanosine 50-triphos-
phate; Hepes, N-2-hydroxyethylpiperazyne-N0-2-ethanesulfonic acid; HIV, human
immunodeﬁciency virus; IPTG, isopropyl-b-D-thiogalactopyranoside; ITC, isothermal
titration calorimetry; LB, Luria–Bertani; MDR, multidrug-resistant; MtUMPK, uridine
50-monophosphate kinase from Mycobacterium tuberculosis; NADH, nicotinamide
adenine dinucleotide; NDP, nucleoside diphosphate; NMP, nucleoside monophos-
phate; NTP, nucleoside triphosphate; PCR, polymerase chain reaction; PDB, Protein
Data Bank; RNA, ribonucleic acid; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide
gel electrophoresis; TB, Terriﬁc Broth; TB, tuberculosis; Tris, tris(hydroxymethyl)ami-
nomethane; UDP, uridine 50-diphosphate; UMP, uridine 50-monophosphate; UMPK,
uridine 50-monophosphate kinase; UTP, uridine 50-triphosphate; XDR, extensively
drug-resistant.
D.C. Rostirolla et al. / Archives of Biochemistry and Biophysics 505 (2011) 202–212 203the role played by proteins of essential and, preferentially, exclusive
biochemical pathways for mycobacterial growth [5].
Rational inhibitor design relies on mechanistic and structural
information on the target enzyme. Enzyme inhibitors make up
roughly 25% of the drugs marketed in United States [6]. Enzymes
offer unique opportunities for drug design that are not available
to cell surface receptors, nuclear hormone receptors, ion channel,
transporters, and DNA [6]. It has been pointed out that one of the
lessons to be learned from marketed enzyme inhibitors is that
the most potent and effective inhibitors take advantage of enzyme
chemistry to achieve inhibition [7]. Moreover, the recognition of
the limitations of high-throughput screening approaches in the
discovery of candidate drugs has rekindled interest in rational de-
sign methods [8]. Accordingly, mechanistic analysis should always
be a top priority for enzyme-targeted drug programs aiming at the
rational design of potent enzyme inhibitors.
Nucleotides are important molecules present in all living organ-
isms as they constitute the building blocks for nucleic acids and
also serve as energy sources for many biochemical reactions [9].
Pyrimidine nucleotides can be synthesized by de novo and salvage
pathways resulting in a common product, the nucleotide uridine
50-monophosphate (UMP) [10]. Subsequent phosphorylation of
UMP yields UDP that leads to the synthesis of all other pyrimidine
nucleotides [11]. Nucleoside monophosphate (NMP) kinases play
an important role in the biosynthesis of nucleotides and represent
a homogeneous family of catalysts related to adenylate kinase (EC
2.7.4.3). They catalyze the synthesis of nucleoside diphosphates
(NDPs), which will be converted to nucleoside triphosphates
(NTPs) by a non-speciﬁc nucleoside diphosphate kinase [12].
UMP kinases (UMPKs) catalyze the reversible transfer of the c-
phosphoryl group from ATP to UMP in the presence of a divalent
cation, usually Mg2+ (Fig. 1) [13]. In general, eukaryotic UMP/
CMP kinases (EC 2.7.4.14) are monomers, phosphorylate with com-
parable efﬁciency both UMP and CMP, and are structurally similar
to other NMP kinases (such as adenylate kinase) [12,14–16]. In
contrast, bacterial UMPKs (EC 2.7.4.22) are speciﬁc for UMP, exist
in solution as stable homohexamers, and do not resemble either
UMP/CMP kinases or NMP kinases from other organisms based
on sequence comparisons [17,18]. Kinetic studies have shown that
bacterial UMPKs can be activated by GTP and/or be subject to feed-
back inhibition by UTP, the major product of the reaction they cat-
alyze [17–21], regulating the balance of purine versus pyrimidine
nucleoside triphosphates synthesis [13].
As pyrimidine biosynthesis is an essential step in the progres-
sion of TB, enzymes of this pathway are attractive antitubercular
drug targets [22]. Homologs to enzymes in the pyrimidine pathway
have been identiﬁed in the genome sequence of M. tuberculosis
[23]. A rapid recombination method for screening and conﬁrma-
tion of gene essentiality has recently been proposed to allow
identiﬁcation of which of the approximately 4000 genes of
M. tuberculosis are worthy of further study as drug targets [24].
The product of pyrH (Rv2883) gene has been shown to be essential
for M. tuberculosis growth by the rapid screening method [24].Fig. 1. Chemical reaction catalyzed by UMPK.Genetic studies have provided evidence that UMPK is essential
for growth in both Gram-negative (Escherichia coli) [25,26] and
Gram-positive bacteria (Streptococcus pneumoniae) [19]. Although
the pyrH gene has been proposed by sequence homology to encode
a UMPK protein [23], there has been no formal biochemical proof
as to ascertain the correct assignment to the open reading frame
of pyrH gene in M. tuberculosis.
In the present work, the pyrH gene from M. tuberculosis strain
H37Rv was PCR ampliﬁed, cloned, and recombinant UMPK
(MtUMPK) was puriﬁed to homogeneity. N-terminal amino acid
sequencing and electrospray ionization mass spectrometry (ESI-
MS) analyses were carried out to conﬁrm the identity of the recom-
binant MtUMPK protein. Initial velocity studies were performed to
evaluate the kinetic parameters of the recombinant MtUMPK. In
addition, isothermal titration calorimetry study of substrates bind-
ing was carried out to demonstrate the order of substrate addition
in the kinetic mechanism of MtUMPK. Protein allosteric regulation
by ATP, GTP, and UTP have also been demonstrated. These results
represent an important step for the rational design of MtUMPK
inhibitors that can further be tested as anti-TB drugs.Materials and methods
Ampliﬁcation, cloning and DNA sequencing of the pyrH gene
The full-length pyrH (Rv2883c) coding region [23] was PCR
ampliﬁed using the genomic DNA from M. tuberculosis H37Rv as
template and a high ﬁdelity proof-reading thermostable DNA poly-
merase (Pfu DNA polymerase, Stratagene). The synthetic oligonu-
cleotides used (forward primer, 50-GTC ATA TGA CAG AGC CCG ATG
TCG CCG GC-30; and reverse primer, 50-TAA AGC TTT CAG GTG GTG
ACC AGC GTT CCG A-30) were designed to contain, respectively,
NdeI and HindIII (New England Biolabs) restriction sites (under-
lined). Dimethyl sulfoxide (DMSO) was added to a ﬁnal concentra-
tion of 10%. The 786-bp amplicon was detected on 1% agarose gel
and puriﬁed utilizing the Quick Gel Extraction kit (Invitrogen).
The PCR fragment was cloned into pCR-Blunt vector (Invitrogen)
and, following transformation of E. coli strain DH10B (Novagen),
the resulting plasmid was isolated utilizing the Qiaprep Spin Mini-
prep kit (Qiagen). Subsequently, the fragment was cleaved with
NdeI and HindIII endonucleases and inserted into the pET-23a(+)
expression vector (Novagen), previously digested with the same
restriction enzymes. The complete pyrH nucleotide sequence was
determined by automated DNA sequencing to corroborate se-
quence identity, integrity and to check the absence of mutations
in the cloned fragment.Expression and puriﬁcation of recombinant MtUMPK
The recombinant plasmid pET-23a(+)::pyrH was transformed
into BL21(DE3) E. coli electrocompetent cells (Novagen), and cells
carrying the recombinant vector were selected on Luria–Bertani
(LB) agar plates containing 50 lg mL1 ampicillin [27]. A single col-
ony was used to inoculate 50 mL of Terriﬁc Broth (TB) medium con-
taining the same antibiotic and grownovernight at 37 C. Aliquots of
this culture (2.5 mL)were used to inoculate 250 mL of TBmedium in
5  1 L ﬂasks supplemented with ampicillin (50 lg mL1) and
grown at 37 C and 180 rpm to an optical density (OD600nm) of 0.4–
0.6. When this OD600 value was reached, the temperature was low-
ered to 30 C andprotein expressionwas carried outwithout isopro-
pyl-b-D-thiogalactopyranoside (IPTG) induction. After 24 h, the cells
(12 g) were collected by centrifugation at 11,800g for 30 min at 4 C
and stored at 20 C. The same protocol was employed for BL21
(DE3)E. coli cell transformedwithpET-23a(+) as control. The expres-
sion of the recombinant protein was conﬁrmed by 12% sodium
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stained with Coomassie Brilliant Blue [28].
Escherichia coli (2 g) cells overproducing the MtUMPK were
resuspended in 20 mL of 50 mM Tris–HCl, pH 7.5 (buffer A), stirred
for 30 min at 4 C in the presence of lysozyme (0.2 mg mL1, Sig-
ma–Aldrich), and disrupted by sonication (eight pulses of 10 s, at
an amplitude value of 60%). The lysate was centrifuged at
38,900g for 30 min to remove cell debris and the supernatant
was treated with 1% (wt/vol) streptomycin sulfate (Sigma–Al-
drich), stirred for 30 min, and the mixture was centrifuged at
38,900g for 30 min. The supernatant containing soluble MtUMPK
was dialyzed against 2 L of buffer A for 3 h.
All puriﬁcation steps were carried out on an ÄKTA system (GE
Healthcare) at 4 C with UV detection at 215, 254, and 280 nm,
and fractions were analyzed by SDS–PAGE. The crude extract was
loaded on a HiPrep 16/10 Q XL (GE Healthcare) anion-exchange
column pre-equilibrated with buffer A. Proteins were eluted using
a 0–300 mM NaCl linear gradient at a ﬂow rate of 1 mL min1.
Fractions containing MtUMPK in NaCl (ca. 280 mM) were pooled
and (NH4)2SO4 was added to a ﬁnal concentration of 1 M, stirred
for 30 min, and clariﬁed by centrifugation at 38,900g for 30 min.
The supernatant was loaded on a Butyl Sepharose High Perfor-
mance (GE Healthcare) hydrophobic interaction column pre-equil-
ibrated with 50 mM Tris–HCl, pH 7.5, containing 1 M (NH4)2SO4.
Proteins were eluted using a 0–100% linear gradient of buffer A
at a ﬂow rate of 1 mL min1. Pooled fractions containing MtUMPK
was dialyzed against buffer A to remove salt and loaded on a Mono
Q 16/10 (GE Healthcare) anion-exchange column. MtUMPK was
eluted in a salt gradient (0–240 mM NaCl) at a ﬂow rate of
1 mL min1. The pooled sample was dialyzed against 50 mM
Tris–HCl, pH 7.5, containing 200 mM NaCl, concentrated using an
AMICON (Millipore Corporation, Bedford, MA) ultra ﬁltration
membrane (MWCO = 10 kDa), and stored at 80 C. Total protein
concentration was determined by the method of Bradford [29],
using the Bio-Rad protein assay kit (Bio-Rad Laboratories) and bo-
vine serum albumin as standard.
Amino acid sequence and mass spectrometry analysis
The N-terminal amino acid residues of homogenous recombi-
nant MtUMPK were determined by automated Edman degradation
sequencing using a PPSQ-21A gas-phase sequencer (Shimadzu)
[30]. Recombinant MtUMPK was analyzed by electrospray ioniza-
tion mass spectrometry (ESI-MS) employing some adaptations
made to the system described by Chassaigne and Lobinski [31].
Samples were analyzed on a Quattro-II triple-quadrupole mass
spectrometer (Micromass; Altrincham, UK), using MassLynx and
Transform softwares for data acquisition and spectrum handling.
Determination of MtUMPK molecular mass
Gel-ﬁltration chromatography was performed on a Superdex
200 (HR 10/30) column (GE Healthcare) pre-equilibrated with
50 mM Tris HCl pH 7.5 containing 200 mM NaCl at a ﬂow rate of
0.4 mL min1, with UV detection at 215, 254 and 280 nm. The
LMW and HMW Gel Filtration Calibration Kits (GE Healthcare)
were used to prepare a calibration curve. The elution volumes
(Ve) of standard proteins (ferritin, catalase, aldolase, coalbumin,
ovalbumin, ribonuclease A) were used to calculate their corre-
sponding partition coefﬁcient (Kav, Eq. (1)). Blue dextran 2000
(GE Healthcare) was used to determine the void volume (Vo). Vt
is the total bead volume of the column. The Kav value for each pro-
tein was plotted against their corresponding molecular mass.
Kav ¼ Ve  VoV t  Vo ð1ÞMultiple sequence alignment
The amino acid sequences of the following UMPK proteins,
whose three-dimensional structures were solved, were included
in the alignment: E. coli (NP_414713.1), Ureaplasma parvum
(YP_001752598.1), Pyrococcus furiosus (NP_579136.1), Sulfolobus
solfataricus (NP_342460.1), and Bacillus anthracis (NC_012659.1).
The UMPK amino acid sequences of S. pneumoniae (YP_816317.1)
and B. subtilis (NP_389533.2) [32] were also included in the align-
ment and compared with M. tuberculosis UMPK (NP_217399.1).
Multiple amino acid sequence alignment was performed by Clu-
stalW [33], using the Gonnet matrix for amino acids substitutions
and considering gap penalties, to identify essential residues for
nucleotide substrate(s) binding, as well as to infer possible similar-
ities in their mechanism of catalysis. For alignment improvement,
8, 23, 11, 5, 5, and 29 amino acids residues were removed from the
E. coli, U. parvum, B. anthracis, S. pneumoniae, B. subtilis, and M.
tuberculosis, respectively.
Functional characterization of MtUMPK
MtUMPK catalytic activity was measured for all puriﬁcation
steps in the forward direction at 25 C, using a coupled spectropho-
tometric assay (0.5 mL ﬁnal volume) as described elsewhere [34],
on an UV-2550 UV/vis spectrophotometer (Shimadzu). In short,
the reaction mixture contained 50 mM Tris–HCl, pH 7.5, 50 mM
KCl, 5 mM MgCl2 buffer; 1 mM phosphoenolpyruvate, 0.2 mM b-
NADH, ﬁxed concentrations of both ATP (3000 lM) and UMP
(600 lM) substrates, 3 U of pyruvate kinase (EC 2.7.1.40) and
2.5 U of L-lactate dehydrogenase (EC 1.1.1.27). The reaction was
started by the addition of MtUMPK. The decrease in absorbance
at 340 nm (eb-NADH = 6.22  10+3 M1 cm1) was continuously
monitored and corrected for non-catalyzed chemical reactions in
the absence of UMP. One unit of MtUMPK is deﬁned as the amount
of enzyme necessary to convert 1 lmol of UMP in UDP per min in
an optical path of 1 cm.
Steady-state kinetics
Determination of the apparent steady-state kinetic parameters
were evaluated at varying concentrations of UMP (0–150 lM)
and a ﬁxed-saturating concentration of ATP (3000 lM), and at
varying concentrations of ATP (0–3000 lM) and a ﬁxed-saturating
level of UMP (600 lM). Initial velocity data were analyzed by Sig-
maPlot (Systat Software, Inc.).
In order to evaluate the speciﬁcity for phosphate acceptor, UMP
was replaced with other nucleoside monophosphates (CMP, dCMP
or dTMP) at different concentrations. The speciﬁcity of the enzyme
as regards the phosphoryl donors was tested by replacing ATP with
3 mM GTP, CTP, and UTP in the standard assay.
Inhibition studies were carried out in the presence of ﬁxed
non-saturating levels of ATP (1300 lM) and ﬁxed-varied UTP
concentration (0, 30, 50, and 70 lM) when UMP was the variable
substrate. Inhibition studies were also carried out in the presence
of ﬁxed non-saturating concentration of UMP (40 lM) and
ﬁxed-varied UTP concentration (0, 20, 50, and 100 lM) when ATP
was the variable substrate. In addition, saturation curves for UTP
(0–400 lM) were carried out at three different sets of experiments:
ﬁxed-non-saturating ATP concentration (1300 lM) corresponding
to its K0.5, and saturating UMP concentration (600 lM = 19  Km);
ﬁxed-non-saturating ATP concentration (1300 lM) corresponding
to its K0.5, and non-saturating UMP concentration (30 lM ﬃ Km);
and ﬁxed-saturating ATP concentration (3000 lM = 2.3  K0.5)
and non-saturating UMP concentration (30 lM ﬃ Km). The maxi-
mal rate for each reaction condition was determined in the absence
of inhibitor. Initial velocity parameters were also analyzed as a
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tion (600 lM) either in the absence or presence of a ﬁxed concen-
tration of GTP (500 lM) to verify whether this substrate has any
effect on the kinetic properties ofMtUMPK (70 nM). Initial velocity
measurements were also carried out as a function of UMP concen-
tration at ﬁxed-saturating ATP concentration (3000 lM) in either
absence or presence of GTP (500 lM).
Hyperbolic saturation curves were ﬁtted by non-linear regres-
sion analysis to the Michaelis–Menten equation (Eq. (2)), in which
v is the steady-state velocity, Vmax is the maximal rate, [S] is the
substrate concentration, and Km is the Michaelis–Menten constant
[35,36]. Sigmoidal curves were ﬁtted to the Hill equation (Eq. (3)),
where K0.5 is the value of the substrate concentration where
v = 0.5 Vmax, and n is the Hill coefﬁcient (indicating the cooperative
index) [35,36].
v ¼ Vmax½S
Km þ ½S ð2Þ
v ¼ Vmax½S
n
Kn0:5 þ ½Sn
ð3Þ
The Ki value for UTP towards UMP was calculated using the
uncompetitive equation (Eq. (4)), in which [I] is the inhibitor con-
centration and Ki is the inhibition constant [35,36].
v ¼ Vmax½S
½S 1þ ½IK i
 
þ Km
ð4Þ
The IC50 value, which deﬁnes the concentration of inhibitor re-
quired to half-saturate the enzyme population, was determined by
ﬁtting the data to Eq. (5), in which vi and vo are, respectively, the
reaction velocity in the presence and in the absence of inhibitor,
vi/vo represents the fractional activity remaining at a given inhibi-
tor concentration (fraction of free enzyme), and n is the Hill coefﬁ-
cient [36].
v i
vo
¼ 1
1þ ½IIC50
 n ð5ÞFig. 2. (A) Twelve percent SDS–PAGE analysis of total soluble proteins. Expression
of MtUMPK of 24-h cell growth after reaching an OD600 nm of 0.4–0.6 in TB medium
without addition of IPTG. Lane 1, Protein Molecular Weight Marker (Fermentas);
lane 2, soluble E. coli BL21 (DE3) [pET-23a(+) (control)] extract; lane 3, soluble E. coli
BL21 (DE3) [pET-23a(+)::pyrH] extract. (B) Twelve percent SDS–PAGE analysis of
pooled fractions fromMtUMPK puriﬁcation steps. Lane 1, Protein Molecular Weight
Marker (Fermentas); lane 2, crude extract; lane 3, HiPrep Q XL 16/10 elution; lane 4,
Butyl Sepharose HP elution and Mono Q 16/10 elution.Isothermal titration calorimetry (ITC)
ITC experiments were carried out using an iTC200 Microcalorim-
eter (MicroCal, Inc., Northampton, MA). The reference cell (200 lL)
was loaded with Milli Q water during all experiments and the sam-
ple cell (200 lL) was ﬁlled with MtUMPK at a concentration of
100 lM. The injection syringe (39.7 lL) contained substrates or
effectors at different concentrations: ATP, ADP, GTP, and UTP at
1.5 mM, UMP at 3 mM, and UDP at 1.8 mM. In addition, titration
was performed with the non-hydrolyzable ATP analog, adenosine
50-(b,c-imido)triphosphate tetralithium salt hydrate (AMP-PNP)
at 1.2 mM to determine the ligand concentration necessary to sat-
urate the enzyme active sites. Subsequently, UMP at 800 lM was
titrated into the sample cell containing MtUMPK (100 lM) and
AMP-PNP at saturating concentration (250 lM). The latter permits
evaluation of any effect that this ATP analog may have on UMP
binding to MtUMPK:AMP-PNP binary complex. The ligand binding
isotherms were measured by direct titration (ligand into macro-
molecule). The enzyme was prepared for ITC analysis by dialysis
against 50 mM Hepes at pH 7.5 containing 50 mM KCl, 5 mM
MgCl2, 200 mM NaCl. The same buffer was used to prepare all li-
gand solutions and Tris, used at the kinetic assays, was replaced
with Hepes due to the high enthalpy of ionization of Tris [37,38].
The stirring speed was 500 rpm at a temperature of 25 C for all
ITC experiments. The ﬁrst titration injection (0.5 lL), which was
discarded in the data analysis, was followed by 17 injections of
2.2 lL each at 180 s intervals. Control titrations (ligand into buffer)were performed to subtract the heats of dilution and mixing for
each experiment prior to data analysis. The data after peak integra-
tion of the isotherm generated by ITC, subtraction of control titra-
tion data and concentration normalization (heat normalized to the
molar ratio), were analyzed by Origin 7 SR4 software (Microcal,
Inc.).
The DG (Gibbs free energy) of binding was calculated using the
relationship described in Eq. (6), in which R is the gas constant
(8.314 J K1 mol1), T is the temperature in K (T = C + 273.15),
and Ka is the association constant at equilibrium. The entropy of
binding (DS) can also be determined by this mathematical formula.
The initial estimates for n, Ka, and DH parameters were reﬁned by
standard Marquardt non-linear regression method provided in the
Origin 7 SR4 software.
DGo ¼ RT lnKa ¼ DHo  TDSo ð6ÞResults and discussion
Ampliﬁcation, cloning and sequencing of the pyrH gene
The 786-bp PCR amplicon was consistent with theM. tuberculo-
sis H37Rv pyrH coding region (data not shown). The product was
puriﬁed and ligated into pET-23a(+) expression vector as described
in Section ‘Ampliﬁcation, cloning and DNA sequencing of the pyrH
gene’. Automated DNA sequencing conﬁrmed the identity and the
absence of mutations in the cloned fragment.
Expression and puriﬁcation of the recombinant MtUMPK
The resulting pET-23a(+)::pyrH recombinant plasmid was elec-
troporated into BL21(DE3) E. coli cells and cultures were grown in
TB medium for 24 h. Analysis by SDS–PAGE indicated that the
supernatant of cell extract (Fig. 2A, lane 3), which was sonicated
and centrifuged, contained a signiﬁcant amount of protein with
subunit molecular mass (ca. 27 kDa) in agreement with the pre-
dicted MW for MtUMPK (27.4 kDa).
The overexpressed protein was puriﬁed by a three-step protocol
consisting of an anion-exchange column (HiPrep Q XL), a hydro-
phobic interaction column (Butyl Sepharose HP) and a strong an-
ion-exchange column (Mono Q). The target protein eluted at
approximately 180 mM of NaCl from the Mono Q column, and
Table 1
Puriﬁcation of MtUMPK from E. coli BL21 (DE3). Typical puriﬁcation protocol from 2 g wet cell paste.
Puriﬁcation step Total protein (mg) Total enzyme activity (U) Speciﬁc activity (U mg1) Puriﬁcation fold Yield (%)
Crude extract 158 722 4.6 1.0 100
HiPrep Q XL 55 977 17.8 3.9 135
Butyl Sepharose 27 863 32 6.9 120
Mono Q 20 154 7.7 1.7 21
206 D.C. Rostirolla et al. / Archives of Biochemistry and Biophysics 505 (2011) 202–212SDS–PAGE analysis showed that recombinant MtUMPK was
homogenous (Fig. 2B, lane 5). This 1.7-fold puriﬁcation protocol
yielded 20 mg of recombinant protein from 2 g of cells, indicating
a 21% protein yield (Table 1). Enzyme kinetic measurements by
NADH-coupled spectrophotometric assay showed that recombi-
nant MtUMPK indeed catalyzes the phosphorylation of UMP. Nev-
ertheless, increase in the speciﬁc activity could be observed in the
presence of high salt concentrations and a pronounced decrease
after salt removal. This difference in activity may be attributed to
ionic strength which, such as pH variations, is recognized to affect
enzyme conformation, stability and activity [39,40]. Gagyi et al.
[18] have also reported the addition of 100 mM NaCl as an ap-
proach to keep the B. subtilis UMPK stability. Accordingly, the
homogenous protein was stored at 80 C 50 mM Tris–HCl, pH
7.5, buffer containing 200 mM NaCl, which resulted in an apparent
maximum velocity of 7.7 U mg1 and allowed the kinetic assays to
be carried out without affecting the coupled enzymes.
Mass spectrometry and N-terminal amino acid sequencing
The subunit molecular mass value was determined to be
27264.08 ± 13 Da by ESI-MS, which is lower than expected from
the predicted amino acid sequence (27395.00 Da), indicating that
the N-terminal methionine (130.92 Da) was removed.
The ﬁrst 22 N-terminal amino acid residues identiﬁed by the
Edman degradation method correspond to those predicted forFig. 3. Amino acids sequence alignment of UMPKs from eight prokaryotes. The residues
residues involved in GTP-binding are boxed [13,41]. (), (:), (.) and (–) indicate identity, s
Amino acid residues were numbered after removing 29 N-terminal amino acids from ththe pyrH gene protein product and corroborate the N-terminal
methionine removal. These results unambiguously identify the
homogenous recombinant protein as the putative MtUMPK.
MtUMPK molecular mass determination
Themolecularmass of thenative enzymewasdeterminedby gel-
ﬁltration chromatography and yielded a single peak with elution
volume corresponding to approximately 106 kDa, suggesting that
MtUMPK is a tetramer in solution (106,000 Da/27264.08 Da ﬃ 3.9),
differing from other bacterial homohexameric UMPKs [17–19].
Multiple sequence alignment
The currently available three-dimensional structures of UMPKs
from several prokaryotic organisms deposited in the Protein Data
Bank, such as E. coli (PDB code: 2BNE, 2BND, 2BNF, and 2V4Y)
[13,41], U. parvum (PDB code: 2VA1) [21], P. furiosus (PDB code:
2BRI and 2BMU) [11], S. solfataricus (PDB code: 2J4J, 2J4K and
2J4L) [20] and B. anthracis (PDB code: 2JJX) [9], allow drug design
based on a detailed model of the target binding site. The experi-
mentally solved structures of E. coli UMPK [13,41] in complex with
its substrates and the allosteric effector permit to propose the ami-
no acid side chains inM. tuberculosis that are involved in ATP, UMP,
and UDP binding as well as residues that participate in GTP-bind-
ing. To this end, multiple sequence alignment was carried out andinferred in E. coli as interacting with ATP, UMP or UDP are shaded in gray and the
trong similarity, weak similarity and gat inclusion among the residues, respectively.
e polypeptide sequence of MtUMPK.
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(M. tuberculosis numbering) amino acid residues are equivalent to
residues in E. coli UMPK [13] that interact with the 20-OH ribose
ring of UMP (Fig. 3). The amino acids Gly77, Gly78, Arg82, and
Thr165, which are involved in UMP a-phosphate interactions, are
conserved among all sequences aligned. The main differences
among UMP binding residues are those associated with uracil
binding. The interactions between E. coli UMPK and the uracil moi-
ety of UMP are between the hydrophilic Thr138 and Asn140 amino
acids, whereas in MtUMPK these interactions are made by the
hydrophobic Met158 and Leu160 residues. As no structural data
for MtUMPK have been available to date, it is tempting to suggest
that these differences may be related to the distinct quaternary
structures of MtUMPK (tetramer) and E. coli UMPK (hexamer),
since site-directed mutagenesis of Thr138 and Asn140 residues
suggested their involvement in subunit contacts in the quaternary
structure of the latter [13]. The interactions between the enzyme
and uracil, ribose, or the UDP a-phosphate moiety are very similar
to those with UMP, although UDP binding involves three additional
amino acid residues [13]. The Lys36 and Gly39 residues (M. tuber-
culosis numbering) are conserved, whereas Gly39 in MtUMPK se-
quence replaces a serine residue present in E. coli UMPK.
The amino acids Lys36, Asp166, Phe191, Asp194, and Asp221 in
MtUMPK are likely involved in ATP interaction since they are con-
served in the E. coli UMPK andMtUMPK polypeptide sequences. On
the other hand, Lys185 in MtUMPK replaces a threonine residue
present in ATP binding site of E. coli UMPK. It is interesting to note
that the Lys residue involved in ATP binding replaces Thr in ﬁve
UMPK sequences [43] as in MtUMPK. In E. coli UMPK, the GTP-
binding site is between two dimers of the hexamer and GTP pro-
motes a rearrangement of its quaternary structure, resulting in a
tighter dimer–dimer interaction [41]. Asp113, which interacts with
the GTP purine moiety, Arg123 and Arg150, both interacting with
the phosphate group, are the most conserved amino acid residues
(Fig. 3). These residues are absent in U. parvum and S. solfataricus
UMPKs and may explain the lack of GTP stimulation of these en-
zymes [20,21].Fig. 4. Apparent steady-state kinetic parameters. (A) Speciﬁc activity (U mg1)
versus [UMP] (lM) at ﬁxed concentration of ATP (3000 lM). (B) Speciﬁc activity
(U mg1) versus [ATP] (lM) at ﬁxed concentration of UMP (600 lM). The MtUMPK
concentration was 70 nM on both assays.MtUMPK kinetic parameters
The dependence of velocity with UMP as variable substrate at
ﬁxed-saturating ATP concentration (3000 lM) followed hyperbolic
Michaelis–Menten kinetics (Fig. 4A), and the apparent constant
values were thus calculated ﬁtting the data to Eq. (2), yielding
the following values: Vmax = 7.5 (±0.3) U mg1 and Km = 31
(±3) lM. These results permit estimate a value of 3.4 (±0.1) s1
for the UMP catalytic constant (kcat) and of 11 (±1)  104 M1s1
for the UMP speciﬁcity constant (kcat/Km). The Michaelis–Menten
constant values are similar to those reported for B. subtilis
(KUMPm = 30 lM) and E. coli (K
UMP
m = 43 lM at pH 7.4) UMPKs [18,41].
The saturation curve for ATP at ﬁxed-saturating UMP concen-
tration (600 lM) was sigmoidal (Fig. 4B), suggesting cooperative
kinetics. Accordingly, the data were ﬁtted to the Hill equation
(Eq. (3)), yielding the following values: Vmax = 8.8 (±0.2) U mg1,
K0.5 = 1299 (±32) lM and n = 3.9 (±0.3). The kcat for ATP is 4.0
(±0.1) s1. The limiting value for the Hill coefﬁcient (n) is four since
we showed that MtUMPK is a homotetramer in solution. The n va-
lue of 3.9 thus indicates strong positive cooperativity for ATP.
As demonstrated for others UMPKs [17,20,21], MtUMPK was
speciﬁc for UMP as the phosphoryl group acceptor as no enzyme
activity was detected with CMP, dCMP or dTMP. The speciﬁcity
for the phosphoryl group donor was tested with GTP, CTP and
UTP, and UMP as the acceptor substrate. No activity was detected
with GTP and CTP. UTP acted as phosphoryl donor at a velocity va-
lue of 0.5 U mg1. This value is 18-fold lower than for ATP(8.8 U mg1), suggesting that ATP is the more likely physiological
phosphate donor for MtUMPK.
UTP has been reported as a common negative regulator of UMP-
Ks from Gram-negative bacteria, Gram-positive bacteria and ar-
chae [20,42,43]. To evaluate the inhibitory effect of UTP on
MtUMPK enzyme velocity, measurements of steady-state rates
were carried out as described in Section ‘Materials and methods’.
Double-reciprocal plots at different UTP concentrations displayed
a pattern of parallel lines, suggesting that UTP acts as an uncom-
petitive inhibitor towards UMP in which Vmax and Km values were
simultaneously reduced (Fig. 5) at ﬁxed non-saturating ATP con-
centration (1300 lM) and varying UMP concentration. Data ﬁtting
to Eq. (4) for uncompetitive inhibition yielded a Ki value of 87
(±5) lM for UTP. On the other hand, the plots of MtUMPK activity
versus ATP concentration in the presence of both non-saturating
UMP (40 lM) and ﬁxed-varied UTP concentrations (0, 30, 50, and
70 lM) were all sigmoidal. Although inhibition by UTP did not
modify the sigmoidal shape of the curve, data ﬁtting to Eq. (3)
yielded increasing, though modest, values for apparent K0.5,
whereas Vmax and the Hill coefﬁcient values remained approxi-
mately constant (Table 2). These features appear to be a common
Fig. 5. Double-reciprocal plot of speciﬁc activity1 (mg U1) versus [UMP]1 (lM1)
at 0, 30, 50 and 70 lM UTP. The MtUMPK concentration was 80 nM.
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[19,20,43].
The saturation curves for UTP inhibition in the presence of
ﬁxed-non-saturating ATP concentration and saturating UMP
concentration, ﬁxed-non-saturating ATP concentration and non-
saturating UMP concentration, and ﬁxed-saturating ATP concen-
tration and non-saturating UMP concentration were all sigmoidal
(data not shown). These data were thus ﬁtted to Eq. (5), yielding
estimates for IC50 values and the Hill coefﬁcient (Table 3). The rates
decreased with increasing UTP concentration, reaching a plateau of
low enzyme activity (below 0.5 U mg1) at high UTP concentra-
tions. The IC50 values of 80 lM (saturating UMP concentration)
and 97 lM (non-saturating UMP concentration) were within
experimental error. These results are in agreement with UTP acting
as an uncompetitive inhibitor towards UMP (Fig. 5), thereby sug-
gesting that UTP preferentially binds to a complex formed between
MtUMPK and UMP (it would have to be a ternary complex because
we showed that ATP binding is followed by UMP binding). Stated
otherwise, as the MtUMPK enzyme mechanism is ordered (ATP
binds ﬁrst), the concentration of MtUMPK:ATP binary complex, to
which UMP binds, is unchanged as ATP concentration in both
experiments were the same (1300 lM). It could be argued thatTable 2
ATP kinetic parameters in the presence of ﬁxed concentrations of UTP.
UTP concentration (lM) Vmaxa nb K0.5c (lM)
0 3.8 ± 0.3 2.4 ± 0.4 1.2 (±0.1)  103
20 3.5 ± 0.3 2.1 ± 0.3 1.3 (±0.2)  103
50 3.9 ± 0.4 2.5 ± 0.5 1.4 (±0.2)  103
100 4 ± 1 2.3 ± 0.9 1.7 (±0.5)  103
a Vmax = maximal rate.
b n = the Hill coefﬁcient.
c K0.5 = value of the substrate concentration in which v = 0.5 Vmax.
Table 3
IC50 and n values for UTP in the presence of different ﬁxed substrate concentrations.
Substrate concentrations IC50a (lM) nb
ATP 1300 lM + UMP 600 lM 80 ± 4 1.5 ± 0.1
ATP 1300 lM + UMP 30 lM 97 ± 7 2.8 ± 0.4
ATP 3000 lM + UMP 30 lM 210 ± 6 3.6 ± 0.3
a IC50 = concentration of inhibitor required to half-saturate the enzyme
population.
b n = the Hill coefﬁcient.increasing UMP ﬁxed concentration (from 30 to 600 lM) would re-
sult in increasing concentration of MtUMPK:ATP:UMP ternary
complex, to which UTP binds, resulting in lower IC50 values for lar-
ger UMP concentrations. However, it should be kept in mind that
the enzyme activity measurements here presented provide a value
for the apparent Km value of UMP and that this value represents an
apparent dissociation constant that may be treated as the overall
dissociation constant of all enzyme-bound species. In short, the
true equilibrium dissociation constant of UMP from MtUMPK:
ATP:UMP ternary complex is not known, thereby precluding a pro-
posal that increasing UMP concentration would result in increasing
ternary complex concentration because the true dissociation
constant value for UMP may be considerably larger than the
concentrations employed here. In any case, the uncompetitive
inhibition cannot be overcome by high UMP substrate concentra-
tions, suggesting that UTP binds to an allosteric (regulatory) site.
In addition, there was a decrease in the Hill coefﬁcient (n) from
2.8 at non-saturating UMP concentration to 1.5 at saturating
UMP concentration (Table 3). It thus appears that increasing UMP
concentration results in decreasing degree of cooperativity. In the
presence of saturating ATP concentration (3000 lM), there was a
2-fold increase in IC50 value for UTP, suggesting that UTP acts as
a competitive inhibitor towards ATP. These data are consistent
with ATP kinetics in which increasing ﬁxed-varied concentrations
of UTP in the presence of ﬁxed-non-saturating UMP concentration
yielded increasing values for apparent K0.5 (Table 2). Moreover,
since we have shown that UTP can act as a poor phosphoryl donor,
it is thus likely that UTP can also bind to ATP binding site of
MtUMPK. These data suggest that UTP either binds to the ATP bind-
ing site with low afﬁnity or to an allosteric site that results in
uncompetitive inhibition towards UMP. Incidentally, it has been
proposed that each subunit of bacterial UMPKs has three distinct
nucleotide-binding sites [43].
GTP has been shown to be a positive effector for bacterial UMP-
Ks [41,43]. The crystal structure of E. coli UMPK bound to GTP has
recently been solved at 2.3 Å [41]. The presence of GTP (500 lM)
resulted in both increased Vmax values (from 2 to 3.2 U mg1) and
afﬁnity (K0.5) of ATP for MtUMPK (from 1335 to 545 lM) (Fig. 6).
In addition, the Hill coefﬁcient value of 4.4 in the absence of GTP
decreased to 1.6 in the presence of GTP (500 lM), suggesting that
this nucleotide decreased the degree of cooperativity of ATP upon
MtUMPK enzyme activity (Fig. 6). These results are in agreement
with previously published results on UMPKs from Gram-positive
bacteria [19,43]. On the other hand, the effect of GTP on UMP
kinetics displayed a slight increase in the Vmax values (from
1.63 ± 0.03 U mg1 in the absence to 2.07 ± 0.05 U mg1 in the
presence of GTP), and no change of Km values for UMP (data not
shown).
Equilibrium binding of ligands assessed by ITC
To further elucidate the MtUMPK kinetic mechanism, titration
microcalorimetry of ligand binding to the recombinant enzyme
was carried out. Equilibrium binding values of ligands were mea-
sured directly by ITC, determining the heat generated or consumed
upon ligand–macromolecule binary complex formation at constant
temperature and pressure. The measured of the heat released upon
binding of the ligands allowed us to derive the binding enthalpy
(DH) of the process, to estimate the stoichiometry of the interac-
tion (n) and the association constant at equilibrium (Ka). The disso-
ciation constant at equilibrium (Kd) could be calculated as the
inverse of Ka (Kd = 1/Ka). Moreover, the Gibbs free energy (DG)
and entropy (DS) of binding were determined from the association
constant values at equilibrium as described in Eq. (6). The ITC data
for binding of ligands to MtUMPK (Fig. 7) are summarized in
Table 4. The overall binding isotherms for ATP, ADP, UDP or
Fig. 6. Effect of GTP (500 lM) on ATP saturation curves. In the absence of effector
(), the curve is sigmoidal. In the presence of effector (), the sigmoidicity is
reduced though still present. The MtUMPK concentration was 70 nM.
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sites (Table 4). The UTP binding isotherm was not well deﬁned to
obtain an adequate ﬁt of the data to any model, probable because
this substrate may exert different and simultaneous effects on
MtUMPK.
The mechanism of phosphoryl transfer of NMP kinases has been
reported to follow a sequential random bi bi kinetic mechanism
[12]. TheMtUMPK appears to deviate from this type of mechanism,
since no signiﬁcant heat changes were obtained for UMP binding,
suggesting that it cannot bind to free enzyme. In contrast, all other
ligands tested do bind to the free enzyme and exhibit exothermic
reactions, as seen by negative changes in the binding enthalpy
(Fig. 7). Interestingly, the binding isotherm of an ATP molecule
does not appear to inﬂuence the afﬁnity for the subsequent one,
as the thermodynamic parameters for ATP binding provide single
DH and Ka values. How can one reconcile these data with positive
cooperativity displayed by the saturation curve (Fig. 4B) of steady-
state kinetics for ATP in the presence of UMP? These data suggest
that ATP binding has a positive heterotropic effect upon UMP bind-
ing to MtUMPK:ATP binary complex, since UMP does not bind to
the free enzyme. The n value of 0.57 sites for the ATP binding refers
to the event of two subunits ofMtUMPK in the cell associating with
each ATP molecule injected. In summary, we propose that ATP
binding triggers a conformational change of MtUMPK that results
in increased afﬁnity for UMP. To provide further experimental evi-
dence for the proposed positive heterotropic effect of ATP, titration
of UMP into a solution containing MtUMPK:AMP-PNP binary com-
plex (a non-hydrolyzable ATP analog) was carried out. The ligand
binding isotherms showed no ITC signal upon UMP binding to free
MtUMPK enzyme (Fig. 7, panel E). On the other hand, the ITC signal
for titration of MtUMPK:AMP-PNP with UMP showed changes in
the degree of heat response upon MtUMPK:AMP-PNP:UMP ternary
complex formation, displaying exothermic and endothermic re-
sponses (Fig. 7, panel F). The ITC data were analyzed with a model
assuming a cooperative ligand binding interaction for a tetrameric
protein. The UMP binding exhibited biphasic behavior (Fig. 7, panel
F), which could be assessed by the endothermic and exothermic
proﬁle of the heat response. The ITC data showed a cooperative
pattern and demonstrated that UMP binds to MtUMPK:AMP-PNP
binary complex (Table 4), even though it could not be demon-
strated an obvious positive cooperative effect with increasing
afﬁnity for UMP as the binding sites are sequentially occupied.
However, positive cooperativity is generally more difﬁcult todistinguish from ITC studies alone, since the tendency is for the
binding sites on any single molecule to saturate together unless
the difference in afﬁnity values between the sites were large. Not-
withstanding, the ITC data are in agreement with the steady-state
kinetics results showing that UMP binds to MtUMPK:ATP binary
complex and that ATP has a cooperative effect on tetrameric
MtUMPK enzyme.
The UDP product binds to free MtUMPK enzyme with higher
afﬁnity than ADP product (Table 4), and both ligands displayed a
stoichiometry of one ligand binding to each monomer of the tetra-
meric enzyme. The larger association constant of UDP as compared
to ADP appears to be enthalpy driven (Table 4). These ITC results
suggest that product release is random. The GTP-binding afﬁnity
is in the same range of UDP (Table 4). These ITC results demon-
strate that GTP is capable of binding to free MtUMPK enzyme with
a stoichiometry close to unity. It is interesting to note that ATP
(substrate) as compared to ADP (product) binding display approx-
imately the same association constant at equilibrium (or Gibbs free
energy), which is a result of the ubiquitous phenomenon of enthal-
py–entropy compensation meaning that entropy losses often ne-
gate enthalpy gains [8]. In short, ITC and steady-state kinetic
results provide evidence MtUMPK follows an sequential ordered
mechanism, in which ATP binds ﬁrst to free enzyme followed by
UMP binding to the MtUMPK:ATP binary complex (Fig. 8). Release
of products is, however, random. The mechanism for S. solfataricus
UMPK has been shown to be random order for either addition of
substrates or release of products [20].Summary
Bacterial UMPKs have been proposed to be attractive drug tar-
gets because their primary amino acid sequence and three-dimen-
sional structures are divergent from their eukaryotic counterparts.
They are unique members of the NMP kinases family of enzymes
and several research groups have demonstrate its essentiality for
different organisms [17,19,25,26,44], and to M. tuberculosis in par-
ticular [24]. Moreover, they are oligomers with an exclusive and
complex control of activity by GTP and UTP, representing an inter-
esting model of allosteric regulation [43]. The elucidation of the
mode of action of MtUMPK is thus warranted. Although the pyrH
gene has been proposed by in silico analysis to encode a UMPK en-
zyme [23], formal biochemical proof was still lacking as regards
the correct assignment to its open reading frame in M. tuberculosis.
Accordingly, here we describe PCR ampliﬁcation of the pyrH coding
region, cloning, heterologous expression, and puriﬁcation of re-
combinant protein to homogeneity. N-terminal amino acid se-
quence and ESI-MS conﬁrmed the identity of the homogeneous
recombinant protein. Steady-state kinetic measurements con-
ﬁrmed that the pyrH gene encodes a UMPK enzyme in M. tubercu-
losis. Size exclusion chromatography showed that MtUMPK is a
tetramer in solution. Multiple sequence alignment analysis al-
lowed identiﬁcation of residues involved in substrate binding
and/or catalysis.
Steady-state kinetic measurements showed that MtUMPK is
speciﬁc for both ATP and UMP substrates. This speciﬁcity for
UMP is not surprising since it has been shown that the Rv1712 lo-
cus in M. tuberculosis codes for a functional cytosine monophos-
phate kinase that preferentially phosphorylates CMP and dCMP,
and that UMP is a poor substrate [45]. In agreement with these re-
sults, E. coli has two distinct enzymes that display substrate spec-
iﬁcity for UMP (UMPK) or CMP (CMP kinase) [46]. Steady-state
kinetics and ITC data suggest a sequential ordered mechanism for
substrate addition to MtUMPK, in which ATP binds ﬁrst to free en-
zyme followed by UMP binding; and a random order for release of
products.
Fig. 7. Isothermal titration calorimetric curves of binding of ligands toMtUMPK (100 lM). (A) Titration of the ATP substrate at a ﬁnal concentration of 248 lM. (B) Titration of
the ADP product at a ﬁnal concentration of 248 lM. (C) Titration of the UDP product at a ﬁnal concentration of 398 lM. (D) Titration of the allosteric effector GTP at a ﬁnal
concentration of 248 lM. (E) Titration of the UMP substrate at a ﬁnal concentration of 497 lM. (F) Titration of the UMP substrate at a ﬁnal concentration of 132 lM in the
presence of the non-hydrolyzable ATP analog (AMP-PNP). The experiments were carried out at constant temperature and pressure.
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Table 4
Association constants and thermodynamic parameters of different ligands binding to MtUMPK.
Ligands na Kab (M1) DHc (kcal mol1) DGd (kcal mol1) DSe (cal mol1 K1) Kdf (lM)
ATP 0.57 ± 0.06 3.0e4 ± 5.7e3 4.8 ± 0.6 6.1 ± 1.2 4.3 ± 0.8 33.3 ± 6.3
ADP 1.0 ± 0.1 1.5e4 ± 3.5e3 2.1 ± 0.4 5.7 ± 1.3 12.1 ± 2.8 66 ± 15
UDP 1.01 ± 0.01 2.1e5 ± 2.4e4 4.9 ± 0.1 7.3 ± 0.8 7.9 ± 0.9 4.8 ± 0.5
GTP 0.80 ± 0.01 2.0e5 ± 2.6e4 5.8 ± 0.1 7.2 ± 0.9 4.6 ± 0.6 5.0 ± 0.6
UMP 2.4e5 ± 1.5e5 0.68 7.34 26.9 4.2 ± 2.6
7.5e4 ± 3.8e4 2.3 6.63 14.6 13.3 ± 6.8
1.5e5 ± 9.3e4 3.0 7.03 13.4 6.7 ± 4.2
1.0e5 ± 5.3e4 7.9 6.84 49.5 10 ± 5.3
a n = number of sites.
b Ka = association constant.
c DH = binding enthalpy.
d DG = Gibbs free energy.
e DS = binding entropy.
f Kd = dissociation constant.
Fig. 8. Proposed kinetic mechanism for MtUMPK.
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and inhibition by UTP, showed that MtUMPK is an allosteric en-
zyme that is subject to a complex control by these metabolites.
The results here described also show that MtUMPK belongs to
the K system. This term was originally proposed by Monod et al.
[47], in which the enzyme exists at equilibrium between two states
with the same catalytic activities, but different substrate afﬁnities
(T of low afﬁnity, and R of high afﬁnity). In the absence of effectors,
ATP has a positive heterotropic effect on UMP binding to MtUMPK
to form the catalytically competent ternary complex. This degree of
cooperativity is decreased in the presence of GTP as there is a low-
ering of the Hill coefﬁcient value, and a decrease in K0.5 value for
ATP, thereby suggesting increased ATP afﬁnity for MtUMPK. This
model may also be applicable to UTP inhibition, in which binding
of UTP displaces the equilibrium for the state with lower afﬁnity
for ATP with no effect on the Hill coefﬁcient and maximum veloc-
ity. Moreover, as UTP is an uncompetitive inhibitor towards UMP,
it appears that UTP can have a dual inhibitory effect on MtUMPK
enzyme activity depending on which substrate is varied. The re-
sults on MtUMPK mode of action show that its cooperativity is
more pronounced than that observed for other UMPKs (n values
of 1.28–2.5) [19,21,43]. In general, the Hill coefﬁcient does not rep-
resent the actual number of sites, unless the cooperativity is high
[35]. Our ﬁndings show that the n value of ATP (3.9) for tetrameric
MtUMPK indicates strong positive cooperativity and it may corre-
spond to the actual number of protomers. Activation of MtUMPK
by GTP and feedback inhibition by UTP imply a role for this enzyme
in coordinating the synthesis of purine versus pyrimidine nucleo-
side triphosphates, and highlights the likely relevance of UMPK
in the metabolism of M. tuberculosis.
The currently available repertoire of antimycobacterial agents
reveals only a handful of comprehensively validated targets,
namely RNA polymerase, DNA gyrase, NADH-dependent enoyl-
ACP reductase, and ATP synthase [48]. The complete genome
sequencing of M. tuberculosis H37Rv strain has accelerated the
study and validation of molecular targets aiming at the rational de-
sign of anti-TB drugs [23]. The target-based rational design of new
agents with anti-TB activity includes functional and structural ef-
forts. However, the ﬁrst step to enzyme target validation must in-
clude experimental data demonstrating that a gene predicted by in
silico analysis to encode a particular protein catalyzes the proposed
chemical reaction. Moreover, it has recently been pointed out thatrecognition of the limitations of high-throughput screening ap-
proaches in the discovery of candidate drugs has rekindled interest
in rational design methods [8]. Understanding the mode of action
of MtUMPK will inform us on how to better design inhibitors tar-
geting this enzyme with potential therapeutic application in TB
chemotherapy. Accordingly, it is hoped that the results here de-
scribed may be useful to the rational design of anti-TB agents
and that they may contribute to our understanding of the biology
of M. tuberculosis.
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